Ressources

Recherchez un centre participant à l’essai clinique AIRFLOW-3 ou recevez les dernières nouvelles sur Nuvaira et les mises à jour multimédia.

Rechercher un centre investigateur

Recherchez un centre près de chez vous qui dispose du traitement par le système de dénervation des poumons dNerva dans le cadre de l’essai clinique AIRFLOW-3.

Centres investigateurs en Europe

Autriche
Klinik Floridsdorf
Vienna, Autriche
France
CHU de la Cavale Blanche
Brest, France
CHU Grenoble-Alpes
Grenoble, France
CHU Arnaud de Villeneuve
Montpellier, France
CHU Pasteur
Nice, France
CHU Bichat-Claude Bernard
Paris, France
CHU Maison Blanche
Reims, France
Nouvel Hôpital Civil
Strasbourg, France
CHU Larrey
Toulouse, France
Allemagne
Thoraxklinik Universitätsklinikum Heidelberg
Heidelberg, Allemagne
Pays-Bas
University Medical Center Groningen
Groningen, Pays-Bas
Amsterdam UMC
Amsterdam, Pays-Bas
Royaume-Uni
Royal Brompton Hospital
Londres, Royaume-Uni

Centres investigateurs en États-Unis

Alabama
University of Alabama Lung Health Center
Birmingham, Alabama
Arizona
Honor Health
Birmingham, Alabama
California
UC Davis Health
Sacramento, CA
Harbor-UCLA Medical Center
Torrance, CA
Florida
Ascension St. Vincent’s
Jacksonville, FL
Illinois
The University of Chicago Medicine
Chicago, IL
AMITA Health Alexian Brothers Medical Center Elk Grove Village
Elk Grove Village, IL
Kentucky
University of Louisville Health
Louisville, KY
Ohio
The Ohio State University Wexner Medical Center
Columbus, OH
Michigan
University of Michigan Health
Ann Arbor, MI
Spectrum Health
Grand Rapids, MI
Massachusetts
Beth Israel Lahey Health
Burlington, MA
Missouri
Washington University Medical Center
St. Louis, MO
North Carolina
Duke University Medical Center
Durham, NC
Pennsylvania
Temple Health Lung Center
Philadelphia, PA
University of Pittsburgh Medical Center
Pittsburgh, PA
South Carolina
Medical University of South Carolina
Charleston, SC
Texas
Houston Methodist Hospital
Houston, TX
St. David’s Medical Center
Georgetown, TX

Contactez-nous pour en savoir plus sur le processus d’orientation des patients

Actualités et médias

Jan 25, 2022

200th Treatment Milestone for AIRFLOW-3 COPD Trial

300 Patients Treated Worldwide with dNerva® Targeted Lung Denervation therapy MINNEAPOLIS, January 25, 2022 – Nuvaira, a developer of novel therapeutic strategies…

Août 11, 2021

Nuvaira Announces AIRFLOW-3 COPD Pivotal Trial Milestone

Nuvaira Announces AIRFLOW-3 COPD Pivotal Trial Milestone 100 Randomized Patients; Inspire’s CEO Tim Herbert appointed Chairman of the Board MINNEAPOLIS, August…

Nov 23, 2020

Nuvaira Announces Published Two-Year Results in COPD Patients treated with Targeted Lung Denervation

AIRFLOW-2 two-year data confirm sustained reduction of severe COPD exacerbation risk vs. a control group. MINNEAPOLIS, Nov. 23, 2020 /PRNewswire/ — Nuvaira, a…

Juin 08, 2020

Nuvaira Announces FDA Breakthrough Designation for AIRFLOW-3 Pivotal Trial Device

Inspire Medical Systems CEO Tim Herbert has joined Nuvaira Board of Directors MINNEAPOLIS, June 8, 2020 – Nuvaira, a developer of novel therapeutic strategies…

Fév 04, 2020

Nuvaira Announces Chief Financial Officer and Pivotal Study Milestone

Seasoned Veteran Tom Griffin Joins Nuvaira’s Executive Team MINNEAPOLIS, Feb. 4, 2020 – Nuvaira, a developer of novel therapeutic strategies to treat obstructive…

Août 19, 2019

Nuvaira Announces Peer-Reviewed Publications of Targeted Lung Denervation Mechanisms of Action and Clinical Outcomes

AIRFLOW-2 randomized, sham-controlled one-year data accepted by AJRCCM MINNEAPOLIS, Aug 19, 2019 – Nuvaira, a developer of novel therapeutic strategies to…

Références

Votre patient est-il est bon candidat pour l’essai AIRFLOW-3 ?